Cardiol Therapeutics (NASDAQ: CRDL) — Perfil da empresa, notícias e dados financeiros
Cardiol Therapeutics focuses on developing innovative CBD treatments for heart diseases, aiming to improve patient outcomes.
Cardiol Therapeutics
Cardiol Therapeutics (TSX:CRDL), (NASDAQ:CRDL) is a biotechnology company focused on researching and developing innovative cannabidiol (CBD) treatments for heart diseases and other medical conditions. With a commitment to scientific excellence, Cardiol's projects include the development of anti-inflammatory therapies aimed at reducing the risk of cardiovascular diseases and improving patient outcomes. The company's objectives center around leveraging their proprietary technologies and pharmaceutical expertise to lead the way in developing safer, more effective CBD-based medicines. Cardiol Therapeutics Class A is also traded on the Nasdaq under the ticker code (NASDAQ:CRDL), enabling a broader international investment base to support its mission in transforming cardiovascular treatment landscapes.
Resumo
Operações
Produtos e/ou serviços de Cardiol Therapeutics
- Development of CardiolRx, a pharmaceutically produced cannabidiol formulation for treating heart failure and inflammatory heart disease.
- Clinical trials for anti-fibrotic and anti-inflammatory therapies targeting cardiovascular diseases.
- Research on small molecules for treating fibrotic diseases, including myocarditis and heart failure.
- Collaboration on the formulation and clinical development of new drug candidates designed to protect heart tissue after acute events.
- Partnerships for advancing the development of diagnostic and therapeutic technologies in cardiovascular medicine.
- Outreach and education initiatives aimed at increasing awareness of heart diseases and the potential benefits of cannabidiol-based treatments.
equipe executiva do Cardiol Therapeutics
- David G. ElsleyPresident, CEO & Director
- Christopher J. WaddickCFO, Corporate Secretary & Director
- Bernard LimChief Operating Officer
- Andrew Warwick HamerChief Medical Officer and Head of Research & Development
- Trevor BurnsInvestor Relations
- John A. GeddesVice President of Corporate Development
Principais indicadores financeiros
Resultados divulgados pela Cardiol Therapeutics , em CAD.
- Cap. de mercado
- 142,2 mi
- Receita (TTM)
- 0
- P/L
- —
- LPA (diluído, TTM)
- -0.3
- Dividend yield
- —
- Margem de lucro
- 0.0%
| Fim do ano fiscal | Receita | Resultado operacional | Lucro líquido |
|---|---|---|---|
| 0 | -34,3 mi | -33,8 mi | |
| 0 | -40,3 mi | -36,7 mi | |
| 0 | -22,5 mi | -21,2 mi | |
| 0 | -30,5 mi | -22,8 mi |